Clinical Trials

70 enrolled

Advanced Lung Neuroendocrine Tumor

NCT05749588 2026-04-16

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Triple Negative Breast Neoplasms

NCT06955169 2026-04-16

MOMENTUM-1

153 enrolled

Meningioma

NCT07062965 2026-04-16

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

400 enrolled

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT05773274 2026-04-15

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

100 enrolled

Metastatic Digestive System Neuroendocrine Tumor G1

NCT04485559 2026-04-13

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

Phase 1 Suspended

50 enrolled

Glioma

NCT04802759 2026-04-13

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Phase 1/2 Recruiting

316 enrolled

Neoplasm Metastasis

NCT07340541 2026-04-13

EVOLVE-BDT

700 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01167530 2026-04-06

RAD001

Phase 1 Completed

26 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03049189 2026-04-06

COMPETE

324 enrolled 15 charts

Neuroendocrine Tumors

NCT06382948 2026-04-03

ADELA

240 enrolled

Advanced Breast Cancer

NCT02962414 2026-04-02

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Phase 4 Active not recruiting

206 enrolled

Seizures, Tuberous Sclerosis

NCT05252585 2026-04-02

A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)

4 enrolled

Tuberous Sclerosis, Angiomyolipoma

NCT07405164 2026-03-31

MK-6482-043

450 enrolled

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT05477576 2026-03-30

ACTION-1

EndocrineGastrointestinalNET

338 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT00819546 2026-03-25

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

MyeloidOther hematologic neoplasm

29 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06428396 2026-03-24

LITESPARK-029

Breast Neoplasms

NCT06943755 2026-03-24

STELLAR-311

Phase 2/3 Recruiting

440 enrolled

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT05573126 2026-03-20

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Phase 1/2 Recruiting

95 enrolled

Breast Neoplasms

NCT05843253 2026-03-20

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

NCT03950609 2026-03-19

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

36 enrolled

Phase 2 Not yet recruiting

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT07477548 2026-03-17

A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies

67 enrolled

Arteriovenous Malformations, Hemangioendothelioma, Hemangioma, Lymphangioma, Nevus, Vascular Malformations

NCT05918302 2026-03-06

LEVEL

Thymus Neoplasms, Neuroendocrine Tumors

NCT05012371 2026-03-05

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

90 enrolled

CNSEndocrineGenitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT04895748 2026-03-03

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Phase 1 Terminated

40 enrolled

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma

NCT07435584 2026-02-27

EVER-RECODE

Phase 1/2 Not yet recruiting

38 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT02811861 2026-02-23

CLEAR

1,069 enrolled 12 charts 2 FDA

Phase 4 Not yet recruiting

Carcinoma, Renal Cell

NCT07426484 2026-02-23

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

80 enrolled

DermatologicLymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Waldenstrom Macroglobulinemia, Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

NCT04199026 2026-02-19

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Phase NA Recruiting

20 enrolled

Sarcoma

NCT02397083 2026-02-13

LEVER

102 enrolled

Gynecologic

Endometrial Hyperplasia

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

333 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms, Recurrence

NCT07407517 2026-02-12

POLARIS

904 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02143726 2026-02-11

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

35 enrolled 14 charts

EndocrineHead & Neck

Thyroid cancer, Hurthle cell

NCT03008408 2026-02-11

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

90 enrolled

Gynecologic

Endometrial Neoplasms

NCT01674140 2026-02-10

e3

1,939 enrolled 15 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT02520063 2026-02-06

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

Phase 1/2 Completed

15 enrolled 18 charts

Breast Neoplasms

NCT05476939 2026-02-05

BIOMEDE 2

433 enrolled

Diffuse Intrinsic Pontine Glioma

NCT01217931 2026-01-30

Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial

180 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05306340 2026-01-30

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

373 enrolled

GynecologicPlasma cellThoracic

Breast Neoplasms

NCT02407509 2026-01-29

RAF/MEK

Phase 1 Completed

104 enrolled

Lung Neoplasms, Multiple Myeloma, Ovarian Neoplasms

NCT03616587 2026-01-28

SERENA-1

396 enrolled

Phase 4 Enrolling by invitation

Breast Neoplasms

NCT02081755 2026-01-27

Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer

336 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

Phase 1 Recruiting

27 enrolled

EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

198 enrolled

Breast Neoplasms

NCT07024173 2026-01-26

A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer

240 enrolled

Breast Neoplasms

NCT05933395 2026-01-20

GERTRUDE

135 enrolled

Neoplasm Metastasis

NCT01087554 2026-01-16

Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer

249 enrolled

Advanced Cancer

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

472 enrolled

Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT03065387 2026-01-12

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

93 enrolled